Since Dukes arrived six months ago as head of Merck Research Labs’ licensing and external affairs, Merck has consolidated and restructured its scattered business development functions, rolled out its regional BD hubs, and rationalized the distinction between equity investments and venture fund investments.
Merck & Co. Inc. executive Iain Dukes told a New York audience March 4 that the company’s consolidation of business development and research capabilities into regional hubs is designed to help the pharma access innovation at the source.
The newly appointed senior vice president of Merck Research Labs’ licensing and external affairs discussed the company’s plans at New York’s Memorial Sloan Kettering Cancer Center, as part of...
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.
After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
